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INTRODUCTION: Astrocytic gliomas are the most common intracranial central nervous system neoplasias, accounting for about 
60% of all primary central nervous system tumors. Despite advances in the treatment of gliomas, no effective therapeutic approach 
is yet available; hence, the search for a more realistic model to generate more effective therapies is essential.
OBJECTIVE: To develop an experimental malignant astrocytoma model with the characteristics of the human tumor.
METHOD: Primary cells from subcutaneous xenograft tumors produced with malignant astrocytoma U87MG cells were inoculated 
intracerebrally by stereotaxis into immunosuppressed (athymic) Rowett rats.
RESULTS: All four injected animals developed non-infiltrative tumors, although other glioblastoma characteristics, such as ne-
crosis, pseudopalisading cells and intense mitotic activity, were observed.
CONCLUSION: A malignant astrocytoma intracerebral xenograft model with poorly invasive behavior was achieved in athymic 
Rowett rats. Tumor invasiveness in an experimental animal model may depend on a combination of several factors, including the 
cell line used to induce tumor formation, the rat strains and the status of the animal’s immune system.
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INTRODUCTION
Astrocytic gliomas are the most common intracranial 
neoplasias, and diffusely infiltrating astrocytomas, 
specifically WHO grade II to IV astrocytomas, account for 
about 60% of all primary central nervous system tumors.1 
Despite the advances in the treatment of gliomas, no 
effective therapeutic approach is available, and the prognosis 
of glioma patients remains poor and is less than 12 months 
of survival after diagnosis of grade IV glioblastoma (GBM).2 
New treatments can only be tested if realistic models are 
available. Therefore, the search for experimental in vitro and 
in vivo models that better mimic the primary characteristics 
of these tumors is essential.
There are few currently available animal brain tumor 
models that exactly simulates the characteristics of human 
malignant gliomas, which include the invasive growth, 
neovascularization, necrosis and pseudopalisading cells.3-5 
Despite this limitation, the current animal models have been 
useful for developing new therapeutic modalities and have 
provided a wealth of information pertaining to the genetic 
events in oncogenesis.6-9 The current models of rat malignant 
glioma use concentrated cell suspensions of tissue culture-
derived brain tumor cells. Most researchers have used the 
stereotactic approach as the implantation technique. The 
stereotactic coordinates are aimed at structures deeper in 
the white matter, usually the caudate nucleus. There are 
two basic types of cell-host combinations: animals that 
are immunologically compatible with tumors that were 
maintained via cell culture for prolonged periods and 306
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xenograft transplantation in which human tumor cells are 
implanted into immunodeficient recipient animals. The use 
of established rat brain tumor cell lines (such as 9L and 
C6) permits experiments in immunologically compatible 
rats (such as Wistar and Fischer rats) (allograft). However, 
such immunologically compatible rat brain tumors usually 
display low invasiveness of the surrounding brain tissue and 
do not recapitulate the histopathology of human primary 
gliomas.3,8,10-13
Xenograft models are based on the intracerebral 
implantation  of  human  brain  tumor  cells  into 
immunodeficient rats (xenotransplantation). The aim of the 
present study was to develop a xenograft model of a human 
brain tumor using a human malignant astrocytoma cell line 
(U87MG) and athymic rats (Rowett).
MATERIAL AND METHODS
Cell culture
The human malignant astrocytoma cell line U87MG 
was obtained from the American Type Culture Collection. 
Monolayers of U87MG cells and primary cells from 
subcutaneous tumors were grown to 70% confluence in 
Dulbecco’s modified Eagle medium (DMEM) supplemented 
with 10% fetal bovine serum, 100 U/mL of penicillin 
G sodium and 100 mg/mL of streptomycin-sulfate in a 
humidified atmosphere at 37°C with 5% CO2. Confluent 
dishes were trypsinized with 0.05% trypsin-0.002% 
ethylenediamine tetraacetic acid (Life Technologies, Inc, 
NY), and the cells were resuspended in DMEM. Primary cell 
cultures were obtained by mincing tumors immediately after 
their removal from the animal.
In vivo xenograft tumor model
Eight female Rowett rats, 8 weeks old with an average 
weight of 140 g, were used for the experiments. To 
establish U87MG xenograft tumors in rats, four rats were 
injected subcutaneously in the right flank with 1 x 105 
cells suspended in 100 mL of DMEM. Flank tumors were 
measured with calipers. Animals were sacrificed when the 
flank tumor grew to a size of 2.5 cm (approximately 35 days 
after inoculation).
Intracranial inoculations were performed in four rats with 
the primary cell culture obtained from subcutaneous tumors. 
The rats were anesthetized with intraperitoneal ketamine 
hydrochloride (90 mg/kg) and placed in a stereotaxic head 
frame (Kopf, Germany). The frontal right lobe was accessed 
by trepanation. Antisepsis of the skin covering the cranium 
was performed using 70% alcohol, and a median incision of 
approximately 1 cm was made. Access to the cranial cavity 
was achieved by means of a right frontal burr hole, 2 mm in 
front of the coronal suture and 2 mm to the side of the sagittal 
suture (Figure 1A). This procedure was carried out using an 
electric mini-drill (Bosch). A total of 1 x 105 cells in 4 mL of 
DMEM was injected 3 mm deep with a Hamilton syringe. 
The needle was left in position for 10 minutes and was then 
withdrawn slowly. The scalp wound was sutured with 5-0 
mononylon. The rats were assessed daily, specifically for 
changes in gait that would suggest a motor deficit and for 
secretions accumulating in the periocular region; when these 
conditions were observed, the rats were sacrificed using a 
thionembutal overdose. Cardiac perfusion was performed 
with 100 mL phosphate-buffered saline (PBS) and 80 mL 
of paraformaldehyde (4%), followed by extraction of the 
brain. Whole brains were fixed in 4% paraformaldehyde 
for one week at room temperature, sliced antero-posteriorly 
in 0.5-cm thick coronal specimens, embedded in paraffin 
blocks and sectioned at 5 µm. Representative tumor sections, 
together with the surrounding cerebral tissue, were mounted 
on microscope slides and stained with hematoxylin-eosin. 
The diameter of the largest section of each tumor sample was 
measured with calipers.
RESULTS
Subcutaneous inoculation
All four injected animals developed a clearly palpable 
tumor after 21 days. Within 35 days of inoculation, all 
tumors reached 2.5±0.2 cm in diameter. Histopathological 
analysis showed the presence of highly proliferative and 
well-vascularized masses. Other features of GBM were also 
identified, including necrotic areas, nuclear pleomorphism, 
mitotic activity and endothelial hyperplasia.
Intracranial tumor implantation
The procedure for implanting the U87MG cells was 
well tolerated. No complication related to the surgical 
or anesthetic procedure was observed. Twenty days 
after implantation, signs of periocular secretion build-up 
were observed. Motor deficit was observed 24 days after 
inoculation, when the rats were sacrificed. No extra-cerebral 
masses were observed. All rats developed brain tumors in the 
form of a single intracerebral mass growing over the cortical 
surface and centered upon the injection site (Figure 1B).
The diameters of the largest 5µm microscopic tumor slice 
section were measured for each sample. The lateral-lateral 
diameter ranged from 0.5 cm to 0.9 cm (average 0.7 cm), 
and the cranio-caudal diameter ranged from 0.3 cm to 0.6 307
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cm (average 0.5 cm).
Microscope analysis of the brain tumors showed the 
presence of neoplastic characteristics resembling human 
GBM, such as neovascularization, hemorrhagic necrotic 
clusters, pseudopalisading cells and mitotic activity (Figure 
2). The brain-tumor interface was clearly seen and did not 
show microscopic infiltration at the borders of the primary 
lesion. Groups of tumor cells were not found beyond the 
edges of the main mass. Tumor cells did not infiltrate either 
the leptomeningeal or the perivascular spaces. There was 
little inflammatory response adjacent to the tumor lesion.
DISCUSSION
Solid malignant tumors are curable when an early 
diagnosis is made and the tumor is radically removed. 
Successful treatment of GBM is still a challenge because 
the tumor is of a considerable size when it is first diagnosed, 
and radical resection is impossible because of its infiltrative 
nature. The degree of tumor invasiveness depends on 
the characteristics of the neoplastic cells and also on 
immunological tumor-host interactions.
Regarding experimental brain tumors, the immunological 
interaction is fundamental to the development of tumor 
masses because the current models are based on tumor cell 
implantation in rats and mice. Basically, two methodologies 
are employed: 1) immunologically compatible tumor 
cells are injected into a receptor animal (allograft) or 2) 
non-immunologically compatible tumor cells are injected 
into immune-deficient animals (xenografts). In the latter 
case, animals can be congenitally immunosuppressed 
(athymic animals, like Rowett rats and nude mice) or can 
be immunosuppressed using anti-rejection drugs, like 
cyclosporin.
In a previous study, we tested a third combination, 
using immunologically compatible cells (C6 cell line) in 
immunocompromised rats (Rowett rat). This combination 
resulted in brain tumors with infiltrative characteristics very 
similar to human GBM,14 with a higher degree of infiltration 
than that observed in the immunologically compatible 
model using the C6 cell line in immunocompetent Wistar 
rats.12 Similar results have been reported with New Zealand 
athymic rats.4 These data suggest that the absence of 
an immunological response, or more precisely a weak 
immunological response, contributes to the invasiveness 
of a brain tumor. Nevertheless, we expected that the 
present xenograft model, which used a human malignant 
astrocytoma cell line (U87MG) in athymic rats (Rowett), 
could generate an infiltrative tumor. However, we observed 
a well-circumscribed tumor with low infiltration of the 
adjacent brain parenchyma under optic microscope analysis.
Guillamo et al.5 also used this third combination (GL15 
GBM cells implanted in immunosuppressed animals), and 
they observed a very infiltrative lesion that reached the 
normal brain parenchyma surrounding the tumor as well as 
normal grey and white matter.
Some possible explanations for this apparent discrepancy 
Figure 1 - A: Schematic of a rat skull showing the inoculation site with 
respect to the sutures (modified from Lal S et al.18). B: Scanned slide of a 
coronal section shows a single tumor mass centered at the inoculation site. 308
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are that immunological interactions have little influence in 
tumor circumscription in experimental animal models or that 
invasiveness to distant places depends on other interactions 
that are more dependent on the combination of the cell type 
and the rat/mouse strain.
C6-induced tumors are strongly influenced by the rat 
strain used for inoculation. Tumors developed in Sprague-
Dawley and Long-Evans animals are encapsulated, delimited 
and well delineated, resembling metastatic lesions15. When 
inoculated into Wistar rat brains, tumors have invasive 
characteristics similar to those of GBM, including necrosis 
and hemorrhage.4
The importance of this immunological combination 
in invasiveness has been investigated by C6 cells 
simultaneous  inoculations  in  subcutaneous  and 
intracerebral sites in Wistar rats, and no tumor development 
was observed. An anti-tumoral immune response induced 
by subcutaneous inoculated cells that thwarted tumor 
growth in the brain is a plausible explanation for 
such a result.12 Similarly, Mourad et al. performed 
combinations of implant experiments (brain and/or 
systemic inoculation) with compatible and non-compatible 
cells, and they concluded that GBM cells are antigenic but 
not immunogenic for their compatible host.16
It is also necessary to emphasize that there is an 
immunological response even in correct immunological 
associations (immunologically compatible graft-host 
or graft-immunosuppressed host). This immunological 
response can be inferred by the presence of a peritumoral 
immunological  response  and  by  the  spontaneous 
disappearance of experimental brain tumors over time.17
It is also possible that strain differences in the cell-
cell interaction or cell-stromal relationships that exist 
between rodents and humans are sufficiently important that 
the invasive characteristics of human xenografts are not 
maintained in these experimental grafts.
In conclusion, we obtained brain tumors with limited 
invasive characteristics in our experimental model using 
U87MG cells implanted in athymic Rowett rats. We 
speculate that the infiltrative or non-infiltrative characteristic 
of a tumor in an experimental animal model depends on the 
combination of the cell line and the rat strain in addition to 
the presence of an active immune system.
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Figure 2 - H&E. Intra-cerebral tumor induced by inoculation of U87MG cells in Provett rats. (a) Brain-tumor interface () with high cellularity and 
neovascularization, 40x; (b) palisading () cells surrounding a necrotic area (#), 100x; (c) brain tissue (left) and tumoral tissue (right), 200x; (d) mitotic 
activity, 400x.309
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